p773–782 

General Information


DRACP ID  DRACP00108

Peptide Name   p773–782 

Sequence  VMAGVGSPYV

Sequence Length  10

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Immune system stimulating peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
N202.A2 Spontaneous tumor in A2×neu mice -- Animals immunized three times with DC pulsed with p369–377 or p773–782 peptide showed ~25–30% tumor growth inhibition, while two immunizations induced ~12–15% tumor growth inhibition and one injection Not available Not available 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  The low-avidity T cell repertoire for a self tumor antigen is functional, can be activated and expanded with the help of costimulation

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00108

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C44H70N10O13S

Absent amino acids  CDEFHIKLNQRTW

Common amino acids  V

Mass  113987

Pl  6.09

Basic residues  0

Acidic residues  0

Hydrophobic residues  4

Net charge  0

Boman Index  1462

Hydrophobicity  118

Aliphatic Index  97

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  1490

Absorbance 280nm  165.56

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 14991605

Title  The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity

Doi 10.1002/eji.200324427

Year  2004

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.